What is rapid-acting insulin?
Rapid-acting insulin lowers blood sugar levels quickly; once injected it can take effect within 15 minutes and can last anywhere from three to five hours, continuing to lower your blood sugar after a meal.
Are there other rapid-acting insulins available?
Yes. Other examples of rapid-acting insulin include:
- Humalog 100 units/mL (available in 3 mL and 10 mL vials, KwikPens, and cartridges)
- NovoLog 100 units/mL (available in vials, FlexPens, and cartridges)
- Apidra 100 units/mL (available in vials and SoloStar pens)
Is the Humalog U-200 KwikPen similar to any of the other rapid-acting insulins?
How is the new Humalog U-200 different?
Although the Humalog U-200 KwikPen has the same active ingredient as Humalog 100 units/mL, the difference is in the strength. Humalog U-200 KwikPen has 200 units/mL, while the other Humalog pens and vials have 100 units/mL.
How will Humalog U-200 be used?
The u-200 KwikPen is to be administered subcutaneously within 15 minutes before eating or right after eating a meal.
What are common side effects of Humalog?
The most common side effect associated with Humalog is hypoglycemia.
Is there anything unique about this FDA approval?
Yes. The Humalog U-200 KwikPen is the first FDA approval of a concentrated mealtime insulin. This medication has twice the amount of insulin lispro compared to the other Humalog 100 unit/mL formulations.
Yes. Some advantages include:
- A longer-lasting pen, requiring fewer pen changes per month.
- Same dose with a smaller amount of insulin to inject.
- No dose conversion from the 100 units/mL to the 200 units/mL will be required.
- You can dial the pen in single-unit increments, with a maximum of 60 units per injection.